Change in TNF- <i>α</i> Receptor Expression Is a Relevant Event in Doxorubicin-Induced H9c2 Cardiomyocyte Cell Death

Abstract excerpt

Doxorubicin (Doxo) is a widely used anticancer drug given for the treatment of leukemias, lymphomas, and solid tumors. Despite its potent antitumor effects, the cardiotoxicity of this drug limits its clinical use. The biochemical mechanisms of Doxo-induced cardiotoxicity remain unclear. Doxo has been shown to induce apoptosis in cardiomyocytes that seems to be responsible, at least in part, for Doxo...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Ischemia and Reperfusion
• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to PARP inhibition in cancer therapy